The state assessed $344 million in penalties against Ethicon, a subsidiary of Johnson & Johnson, in January 2020, after ruling the company made “misleading and potentially harmful statements” in advertisements and instructional brochures for nearly two decades.
A district court of appeals later ruled $42 million of the penalties were unjustified due to lack of evidence pertaining to statements made by sales representatives.
Ryan Carbain, a spokesperson for Johnson & Johnson, told The San Francisco Chronicle the company plans to appeal to the state Supreme Court.
“Ethicon responsibly communicated the risks and benefits of its transvaginal mesh products to doctors and patients and in full compliance with U.S. Food and Drug Administration laws,” Mr. Carbain said.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.